Literature DB >> 23128029

Laser in situ keratomileusis using optimized aspheric profiles and cyclotorsion control to treat compound myopic astigmatism with high cylinder.

Jorge L Alió1, Ana B Plaza-Puche2, Lorena M Martinez2, Magda Torky2, Luis F Brenner2.   

Abstract

PURPOSE: To evaluate the visual outcomes after laser in situ keratomileusis (LASIK) surgery to correct primary compound myopic astigmatism with high cylinder performed using a fast-repetition-rate excimer laser platform with optimized aspheric profiles and cyclotorsion control.
SETTING: Vissum Corporation and Division of Ophthalmology, Universidad Miguel Hernández, Alicante, Spain.
DESIGN: Retrospective consecutive observational nonrandomized noncomparative case series.
METHODS: Eyes with primary compound myopic astigmatism and a cylinder power over 3.00 diopters (D) had uneventful LASIK with femtosecond flap creation and fast-repetition-rate excimer laser ablation with aspheric profiles and cyclotorsion control. Visual, refractive, and aberrometric outcomes were evaluated at the 6-month follow-up. The astigmatic correction was evaluated using the Alpins method and Assort software.
RESULTS: The study enrolled 37 eyes (29 patients; age range 19 to 55 years). The significant reduction in refractive sphere and cylinder 3 months and 6 months postoperatively (P<.01) was associated with improved uncorrected distance visual acuity (P<.01). Eighty-seven percent of eyes had a spherical equivalent within ±0.50 D; 7.5% of eyes were retreated. There was no significant induction of higher-order aberrations (HOAs). The targeted and surgically induced astigmatism magnitudes were 3.23 D and 2.96 D, respectively, and the correction index was 0.91. The safety and efficacy indices were 1.05 and 0.95, respectively.
CONCLUSIONS: Laser in situ keratomileusis for primary compound myopic astigmatism with high cylinder (>3.00 D) performed using a fast-repetition-rate excimer laser with optimized aspheric profiles and cyclotorsion control was safe, effective, and predictable and did not cause significant induction of HOAs.
Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23128029     DOI: 10.1016/j.jcrs.2012.07.037

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  6 in total

1.  Factors associated with changes in posterior corneal surface following photorefractive keratectomy.

Authors:  Achia Nemet; Michael Mimouni; Igor Vainer; Tzahi Sela; Igor Kaiserman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-07       Impact factor: 3.117

2.  Comparative analysis of the efficacy of astigmatic correction after wavefront-guided and wavefront-optimized LASIK in low and moderate myopic eyes.

Authors:  Mounir A Khalifa; Mahmoud F Alsahn; Mohamed Shafik Shaheen; David P Pinero
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

3.  Clinical outcomes of wavefront-guided laser in situ keratomileusis to treat moderate-to-high astigmatism.

Authors:  Steven C Schallhorn; Jan A Venter; Stephen J Hannan; Keith A Hettinger
Journal:  Clin Ophthalmol       Date:  2015-07-13

4.  Comparison of Wavelight Allegretto Eye-Q and Schwind Amaris 750S excimer laser in treatment of high astigmatism.

Authors:  Maja Bohac; Alma Biscevic; Mateja Koncarevic; Marija Anticic; Nikica Gabric; Sudi Patel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-23       Impact factor: 3.117

Review 5.  Small incision lenticule extraction (SMILE) in the correction of myopic astigmatism: outcomes and limitations - an update.

Authors:  Jorge L Alió Del Barrio; Verónica Vargas; Olena Al-Shymali; Jorge L Alió
Journal:  Eye Vis (Lond)       Date:  2017-11-15

6.  Comparison of Small Incision Lenticule Extraction Surgery With and Without Cyclotorsion Error Correction for Patients With Astigmatism.

Authors:  Pei Chen; Yiming Ye; Na Yu; Xiaoying Zhang; Jiexu He; Hua Zheng; Han Wei; Jing Zhuang; Keming Yu
Journal:  Cornea       Date:  2019-06       Impact factor: 2.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.